Global Vertigo Market: Industry Analysis & Outlook (2017-2021)

1
Industry Research by Koncept Analytics
Global Vertigo Market Industry Analysis
Outlook -----------------------------------------
(2017-2021)
November 2017
2
Executive Summary
Vertigo is a medical condition where a person
feels as if they or the objects around them are
moving when they are not. Often it feels like a
spinning or swaying movement. This may be
associated with nausea, vomiting, sweating, or
difficulties walking. It is typically worsened
when the head is moved. Vertigo is the most
common type of dizziness. The causes for vertigo
can be divided into two categories Peripheral
and Central. Peripheral is linked to the inner
ear whereas central is linked to problems in
Central Nervous System. Peripheral vertigo can be
further segmented into five major categories
Benign paroxysmal positional vertigo (BPPV),
Acute Unilateral Vestibulopathy, Menieres
Disease and Vestibular Schwannoma. Amongst all
the stated indication, Menieres disease
represents the largest growth opportunity for the
market players with its continuously rising
incidence. Growth of global vertigo market is
expected to be driven by factors such as rising
incidence and prevalence of peripheral etiologies
of vertigo, increasing geriatric population,
growing healthcare expenditure and improving
disposable income. Further, the market growth
could be hindered by side effects of currently
prescribed medication, the high cost of treatment
and tedious drug approval process. The key trends
for the market include extensive research
development and different approaches being
adopted by drug manufacturers in order to target
vertigo. A key drug OTIVIDEX, which is currently
in third phase of clinical trials and is being
developed by Otonomy Inc., is discussed in the
report. The drug is easier to use and provides a
higher and sustained concentration of
dexamethasone relative to existing injections.
Further, it is anticipated to provide a
well-accepted treatment option for Menieres
Disease, if successfully developed. The report
Global Vertigo Market Industry Analysis
Outlook (2017-2021) analyzes the development of
this market, with focus on Europe and US regions.
The major trends, growth drivers as well as
issues being faced by the market are discussed in
detail in this report. The four major players
involved in the development of breakthrough drug
therapy for vertigo Auris Medical Holding AG.,
Sensorion SA, Otonomy, Inc. and Sound
Pharmaceuticals, Inc. are being profiled along
with their key financials and strategies for
growth.
3
All of the drugs presently available to treat
acute vertigo episodes have sedative effects,
which impairs central compensation mechanisms and
the patients ability to function normally while
being treated. Companies have realized the need
for an effective solution and are spending
heavily on research and development of a novel
therapy in order to reap the first movers
advantage.
Global Recurrent Vestibular Vertigo Patient
Forecast (2016-2021)

• In 2016, million people were recorded to be
  suffering from recurrent vertigo crisis and this
  patient volume is expected to be recorded at
  million in 2021, thereby, growing at a CAGR of
  from 2016 to 2021.
• By 2021, the global MD patient volume is
  forecasted to be recorded at million,
  increasing from million in 2016, depicting an
  anticipated CAGR of , spanning from 2016 to
  2021.
• In 2016, MD accounted for highest volume share of
  treatable patients with share, followed by
  BPPV and acute unilateral vestibulopathy with
  and shares, respectively.

Global Menieres Disease Patient Forecast
(2016-2021)
Global Treatable Vertigo Patient by Indication
(2016)
4
The market players indulged in the development of
novel therapies to cure vertigo crisis are
focusing on different approaches in terms of
mechanism of action of drug.
Europe Recurrent Vestibular Vertigo Patient
Forecast (2016-2021)

• In 2016, the volume of recurrent vertigo patients
  was noted at million and is expected to be
  recorded at million in 2021, growing at a CAGR
  of , spanning from 2016 to 2021.
• The US recurrent vestibular vertigo patient
  volume was recorded at million and is expected
  to reach million in year 2021. The patient pool
  is expected to grow at a CAGR of .
• In Europe, MD accounted for highest share for
  treatable patient volume with , followed by
  BPPV and acute unilateral vestibuloapathy with
  and shares, respectively.

The US Recurrent Vestibular Vertigo Patient
Forecast (2016-2021)
Europe Treatable Vertigo Patient by Indication
5
For Report Purchase Click Belowhttp//www.koncep
tanalytics.com/Researchreport/global-vertigo-marke
t-industry-analysis-outlook-2017-2021-27471.aspx
Disclaimer
Contact Us
This is a licensed product of Koncept Analytics.
You cannot reproduce, publish, distribute,
publicly display, sell or create other works from
this report or use them in any way for commercial
purpose without our prior permission. Further,
you cannot copy this material, by any means
(including electronic copies), for distribution
to others unless you have purchased the corporate
license of this report. We believe the sources
are reliable, but Koncept Analytics does not
warranty the accuracy or completeness of the
data. The data presented in the report is updated
at the publication date but is subject to change
at subsequent releases. All possible efforts have
been made to ensure accuracy of data. However,
investors should not completely rely on the
information given in this report and must make
decisions based on their own investment strategy,
risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T
91-120-4130959 M 91-9871694789vikas_at_konceptana
lytics.com
www.konceptanalytics.com